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We investigated whether structurally different sodiumeglucose cotransporter (SGLT) 2 inhibitors, when
co-administered with dipeptidyl peptidase-4 (DPP4) inhibitors, could enhance glucagon-like peptide-1
(GLP-1) secretion during oral glucose tolerance tests (OGTTs) in rodents. Three different SGLT inhib-
itorsd1-(b-D-Glucopyranosyl)-4-chloro-3-[5-(6-ﬂuoro-2-pyridyl)-2-thienylmethyl]benzene (GTB), TA-
1887, and canagliﬂozindwere examined to assess the effect of chemical structure. Oral treatment with
GTB plus a DPP4 inhibitor enhanced glucose-induced plasma active GLP-1 (aGLP-1) elevation and sup-
pressed glucose excursions in both normal and diabetic rodents. In DPP4-deﬁcient rats, GTB enhanced
glucose-induced aGLP-1 elevation without affecting the basal level, whereas metformin, previously re-
ported to enhance GLP-1 secretion, increased both the basal level and glucose-induced elevation. Oral
treatment with canagliﬂozin and TA-1887 also enhanced glucose-induced aGLP-1 elevation when co-
administered with either teneligliptin or sitagliptin. These data suggest that structurally different
SGLT2 inhibitors enhance plasma aGLP-1 elevation and suppress glucose excursions during OGTT when
co-administered with DPP4 inhibitors, regardless of the difference in chemical structure. Combination
treatment with DPP4 inhibitors and SGLT2 inhibitors having moderate SGLT1 inhibitory activity may be a
promising therapeutic option for improving glycemic control in patients with type 2 diabetes mellitus.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
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d/4.0/).across cell membranes. SGLT1 is highly expressed on the brush-
border membrane in the proximal small intestine, and is respon-
sible for dietary glucose absorption (1). By contrast, SGLT2 is mainly
present in the proximal convoluted tubule of the kidney, and plays
a critical role in renal glucose reabsorption (1). In patients with type
2 diabetes mellitus (T2DM), inhibition of SGLT2 increases urinary
glucose excretion and reduces plasma glucose independently of
insulin.
Canagliﬂozin is the ﬁrst SGLT2 inhibitor approved in the United
States for the treatment of T2DM (2) and has been reported to in-
crease the concentrations of circulating glucagon-like peptide 1
(GLP-1) in healthy subjects (3). GLP-1 is an incretin hormone
secreted from intestinal L-cells in response to dietary ingestion, and
it has therapeutic potential in the treatment of T2DM because of its
insulinotropic and glucagonostatic effects (4). Although the
contribution of SGLTs to GLP-1 secretion is controversial, the dualnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
T. Oguma et al. / Journal of Pharmacological Sciences 132 (2016) 255e261256SGLT1/2 inhibitor LX4211 increases GLP-1 concentration and sup-
presses glucose excursions after meal challenges in patients with
T2DM (5). In addition, we have previously demonstrated that
combined treatment with canagliﬂozin and a dipeptidyl peptidase-4
(DPP4) inhibitor enhanced plasma active GLP-1 (aGLP-1) levels
during oral glucose tolerance tests (OGTTs) in normal and diabetic
rats (6, 7). As glucose is a major stimulant for GLP-1 secretion,
enhanced GLP-1 secretion is likely to result from elevated glucose
contents in the gastrointestinal tract after treatment with SGLT in-
hibitors. However, it is unclear whether other SGLT inhibitors that
have different chemical structures also enhance GLP-1 secretion and
delay intestinal glucose absorption.
We hypothesized that, when co-administered with DPP4 in-
hibitors, enhancement of plasma aGLP-1 elevation is the common
pharmacological effect of all SGLT inhibitors, regardless of their
chemical structure. To address this hypothesis, we assessed the
effects of structurally diverse novel SGLT2 inhibitors, C-glucosides;
1-(b-D-Glucopyranosyl)-4-chloro-3-[5-(6-ﬂuoro-2-pyridyl)-2-
thienylmethyl]-benzene (GTB) and canagliﬂozin, and an N-gluco-
side; TA-1887 on plasma aGLP-1 levels when each was co-
administered with a DPP4 inhibitor or when administered to
DPP4-deﬁcient rats. In addition, we compared the effects of GTB
and metformin, an antidiabetic drug that has been reported to
enhance GLP-1 secretion in both humans and rodents (8), on
plasma aGLP-1 levels with or without oral glucose-loading to
determine the difference in the mode of action of these agents.
2. Materials and methods
2.1. Reagents and chemicals
GTB, (2S)-2-Cyano-1-[trans-4-(morpholinocarbonyl)cyclo-
hexylamino]acetylpyrrolidine (CMA), canagliﬂozin, TA-1887, ten-
eligliptin, sitagliptin, and tofogliﬂozin were prepared by Mitsubishi
Tanabe Pharma Corporation (Kanagawa, Japan). Metformin was
purchased from Wako Pure Chemical Industries (Osaka, Japan). All
other chemicals were of reagent grade or tissue culture grade.
2.2. Cell-based assays
Expression plasmids containing human SGLT1 (hSGLT1) and
human SGLT2 (hSGLT2) were stably transfected into Chinese
hamster ovary (CHO)eK1 cells, which were then seeded into 24-
well plates at a density of 4  105 cells/well in Ham's F-12 me-
dium containing 10% fetal bovine serum. To evaluate hSGLT1 and
hSGLT2 transporter activities, the cells were incubated with 0.3 or
0.5 mM a-methyl-D-glucopyranoside (AMG; SigmaeAldrich, St.
Louis, MO, USA) in the presence of 16.7 mCi/mL [14C]AMG (Perki-
nElmer, Waltham, MA, USA) at 37 C for 2 h in an assay buffer
containing 50-mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), 20-mM Tris Base, 5-mM KCl, 1-mM MgCl2, 1-mM
CaCl2, and 137-mM NaCl at pH 7.4. We conﬁrmed the linear range
of [14C]AMG uptake to 2.5 h, and selected 2 h to conduct the assay
with a wide dynamic range. Radioactive counts in the cells were
determined using a liquid scintillation counter (PerkinElmer).
Protein concentrations were measured using the CoomassiePlus
Protein Assay Kit (Pierce, Rockford, IL, USA).
2.3. In vivo studies
2.3.1. Animal procedures
All animal experimental procedures were approved by the
Institutional Animal Care and Use Committees of Mitsubishi Tanabe
Pharma Corporation and Ina Research (Nagano, Japan). Male F344/
NSlc rats were purchased from Japan SLC (Shizuoka, Japan). MaleF344/DuCrlCrlj and SpragueeDawley (SD) rats were purchased
from Charles River Japan (Kanagawa, Japan). Male C57BL/KsJ-db/db
Jcl (db/db) mice were purchased from CLEA Japan (Tokyo, Japan).
Experimental animals were housed in a temperature and humidity
controlled room on a 12-h light/dark cycle, and were provided
access to water and standard commercial diet, CRF-1 (Oriental
Yeast Co., Tokyo, Japan) ad libitum. Test compounds for oral gavage
were prepared in 0.5% carboxymethylcellulose containing 0.2%
Tween 80, or 0.5% hydroxypropyl methylcellulose.
2.3.2. OGTT in F344 rats and db/db mice
Overnight-fasted 9-week-old F344 rats or 13-week-old db/db
mice were orally administered test compounds and a glucose so-
lution (2 g/kg) simultaneously. Blood was then collected from the
tail vein into chilled tubes containing ethylenediaminetetraacetic
acid dipotassium salt (EDTA-2K; ﬁnal concentration: 2.5 mM) and a
DPP4 inhibitor (Cat# DPP4-010; Millipore, Billerica, MA, USA; ﬁnal
concentration: 50 mM) at different sampling points. Plasma was
separated by centrifugation and stored at 80 C until use for
measurement.
2.3.3. Determination of metabolic parameters
Glucose concentrations in plasma and hydrolyzed samples as
described above were determined using a Glucose CII-Test Wako
Kit (Wako Pure Chemical Industries). Plasma insulin concentrations
were measured using an enzyme-linked immunosorbent assay
(ELISA) kit (Millipore). Plasma aGLP-1 concentrations were
measured using ELISA kit (Millipore or Epitope Diagnostics, San
Diego, CA) after solid-phase extraction with an Oasis HLB mElution
plate (Waters, Milford, MA, USA). Plasma aGLP-1 levels were
expressed as relative values normalized to the baseline of plasma
GLP-1 concentrations per ﬁgure because the absolute concentra-
tions of GLP-1 measured using different kits considerably vary due
to differences in standardization, whereas similar responses of GLP-
1 were observed using either kit. The baseline values were taken as
the plasma aGLP-1 concentrations at 0 h in the vehicle group.
2.4. Statistical analysis
Data are presented per group as means ± standard error of the
mean. The peak values were represented as the highest values of
each plasma parameter during OGTT. The incremental change in
the area under the curve (DAUC; deﬁned as the AUC above the
baseline value) was calculated by the trapezoidal rule (a technique
for approximating AUC by dividing the AUC into several trapezoids
and summing the area of these trapezoids). Statistical differences
between vehicle and single treatment groups or between a DPP4
inhibitor and combination treatment groups were determined by
one-way analysis of variance followed by a parametric Dunnett's
multiple comparison test or Student's t-test, as appropriate. Sta-
tistical analyses were performed using either SAS (SAS Institute,
Cary, NC, USA) or Prism software (GraphPad, San Diego, CA, USA).
Probabilities less than 5% (P < 0.05) were considered statistically
signiﬁcant.
3. Results
3.1. SGLT and DPP4 inhibition
The chemical structures of GTB, TA-1887, and canagliﬂozin are
shown in Supplementary Fig. 1. IC50 values of GTB against hSGLT1
and hSGLT2 were 966 ± 223 nM (n ¼ 3) and 1.5 ± 0.1 nM (n ¼ 6),
respectively. IC50 values of the other SGLT inhibitors are shown in
Supplementary Table 1. Among these SGLT inhibitors, GTB and TA-
1887 were the potent SGLT2 inhibitor, and TA-1887 had the most
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shows the IC50 values of CMA, teneligliptin, and sitagliptin against
human DPP4 activity. CMA exhibited more potent inhibitory ac-
tivity against hDPP4 than sitagliptin.
3.2. Effects of GTB plus a DPP4 inhibitor on plasma parameters in
normal and diabetic rodents
To determine whether oral treatment with GTB affects GLP-1
secretion, we measured plasma parameters during OGTT in nor-
moglycemic F344 rats (F344/NSlc) with and without the co-
administration of CMA, a novel DPP4 inhibitor, which prevents
aGLP-1 degradation. In rats treated with CMA (3 mg/kg), plasma
glucose level slightly decreased and plasma insulin level markedly
increased (Fig. 1). Plasma aGLP-1 level was elevated immediately
after oral glucose-loading, but DAUC0e5h of plasma aGLP-1 was
unchanged. By contrast, in rats treated with CMA (3 mg/kg) and
GTB (10 and 30 mg/kg), plasma glucose elevation was further
reduced compared with that in rats treated with CMA alone, and
plasma aGLP-1 elevation was enhanced in a manner dependent on
the dose of GTB.
We previously reported that combined treatment with cana-
gliﬂozin and sitagliptin increased plasma GLP-1 levels in normal
mice (7). To explore the effect of GTB on plasma aGLP-1 levels in
diabetic animals, we examined combined treatment with GTB and
CMA during OGTT in db/db mice. This strain develops signiﬁcant
obesity, fasting hyperglycemia, and hyperinsulinemia within 6
weeks of age and is used as a murine model of spontaneous T2DM
(9). Inhibition of DPP4 by CMA (3 mg/kg) did not signiﬁcantlyFig. 1. Effects of GTB combined with CMA on plasma glucose, insulin, and aGLP-1 levels dur
plasma glucose levels. (B) Time course (upper panel) and peak (lower panel) of plasma insul
aGLP-1 levels. GTB (10, 30 mg/kg), CMA (3 mg/kg), and glucose solutions (2 g/kg) were simul
presented as the mean ± SEM. (N ¼ 5e6). **P < 0.01 vs vehicle group by t-test; **P < 0.01 vs
hoc test.change plasma glucose and insulin levels after glucose-loading, but
additional GTB (10 mg/kg) treatment further reduced plasma
glucose excursions (Fig. 2). Treatment with either CMA (3mg/kg) or
GTB (10 mg/kg) caused elevated plasma aGLP-1 levels, and treat-
ment with both CMA (3 mg/kg) and GTB (10 mg/kg) augmented
that plasma aGLP-1 elevation extensively. These data demonstrate
that combined treatment with GTB and CMA increases plasma
aGLP-1 levels in both normal and diabetic rodents.3.3. Effect of GTB on plasma aGLP-1 levels with or without glucose-
loading in DPP4-deﬁcient rats
Subsequently, we examined the effects of GTB on plasma aGLP-1
levels with or without glucose-loading to analyze the involvement
of SGLT1. To eliminate potential off-targeting effects of CMA, we
used DPP4-deﬁcient F344 rats (F344/DuCrlCrlj), which are a sub-
strain of F344 rats lacking endogenous DPP4 enzymatic activity
(10). In glucose-loaded DPP4-deﬁcient rats, metformin (300mg/kg)
slightly reduced plasma glucose excursion and modestly elevated
plasma aGLP-1 levels, consistent with data in previous reports (11)
(Fig. 3). Similar to combined treatment with CMA, the use of GTB
alone (at 10 and 30 mg/kg) suppressed plasma glucose elevations
and robustly increased plasma aGLP-1 levels in DPP4-deﬁcient rats
in a dose-dependent manner. However, in DPP4-deﬁcient rats
without glucose-loading, GTB did not change DAUC0e5h of plasma
aGLP-1 at the same doses (Fig. 4). By contrast, metformin (300 mg/
kg) signiﬁcantly increased plasma aGLP-1 levels without glucose-
loading in the DPP4-deﬁcient rats. These data suggest thating OGTT in normal F344 rats. (A) Time course (upper panel) and peak (lower panel) of
in levels. (C) Time course (upper panel) and DAUC0e5h (lower panel) of relative plasma
taneously administered to 9-week-old F344/NSlc rats at time 0 by oral gavage. Data are
vehicle group, and ##P < 0.01 vs CMA group by one-way ANOVA with Dunnett's post
Fig. 2. Effects of GTB combined with CMA on plasma glucose, insulin, and aGLP-1 levels during OGTT in db/dbmice. (A) Time course (upper panel) and peak (lower panel) of plasma
glucose levels. (B) Time course (upper panel) and peak (lower panel) of plasma insulin levels. (C) Time course (upper panel) and DAUC0e5h (lower panel) of plasma aGLP-1 levels.
GTB (10 mg/kg), CMA (3 mg/kg), and glucose solutions (2 g/kg) were simultaneously administered to db/db mice at time 0 by oral gavage. Data are presented as the mean ± SEM.
(N ¼ 8). **P < 0.01 vs vehicle group; ##P < 0.01 vs CMA group by one-way ANOVA followed by t-test.
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induced by GTB, but not for that by metformin.
3.4. Effect of canagliﬂozin and TA-1887 in combination with DPP4
inhibitors on plasma aGLP-1 levels
To compare the combined effects of structurally diverse SGLT
inhibitors with DPP4 inhibitors on plasma aGLP-1 levels, we
examined canagliﬂozin and TA-1887 in combination with ten-
eligliptin and sitagliptin in DPP4-positive F344 rats (F344/NSlc)
during OGTT. Although inhibition of DPP4 by teneligliptin (5 mg/
kg) or sitagliptin (10 mg/kg) alone did not elevate plasma aGLP-1
levels at 2 h after glucose-loading, additional treatment with can-
agliﬂozin (30 mg/kg) or TA-1887 (30 mg/kg) in combination with
these agents signiﬁcantly elevated plasma aGLP-1 levels (Fig. 5).
These data suggest that dual treatment with structurally different
SGLT2 inhibitors plus DPP4 inhibitors results in plasma aGLP-1
elevation, regardless of the difference in chemical structure. In
addition, we assessed the effect of 3 mg/kg canagliﬂozin on plasma
aGLP-1 levels and intestinal glucose contents. In glucose-loaded
DPP4-deﬁcient rats, 3 mg/kg canagliﬂozin prolonged plasma
aGLP-1 elevation and signiﬁcantly increased plasma aGLP-1
AUC0e4h (Supplementary Fig. 2). Compared with 1 mg/kg tofogli-
ﬂozin, a highly selective SGLT2 inhibitor, 3 mg/kg canagliﬂozin
signiﬁcantly reduced plasma glucose excursions and increased the
glucose content in the small intestine 1 h after sucrose-loading
(Supplementary Fig. 3). These ﬁndings suggest that 3 mg/kg can-
agliﬂozin increases plasma aGLP-1 levels in glucose-loaded DPP4-
deﬁcient rats as well as GTB, and this effect may be caused
through SGLT1 inhibition. The Cmax of the clinical dose ofcanagliﬂozin (100 mg/kg/day) and tofogliﬂozin (20 mg/day) in
human plasma was similar to that in the plasma of SD rats after
receiving 3 mg/kg canagliﬂozin and 1 mg/kg tofogliﬂozin, respec-
tively. Supplementary Table 3 shows the Cmax values of canagli-
ﬂozin (3mg/kg) and tofogliﬂozin (1mg/kg) in the plasma of SD rats.
The Cmax values of unbound canagliﬂozin and tofogliﬂozin were
estimated as 7.1e12.8 ng/mL (16.0e18.1 nM) and 58.1e61.7 ng/mL
(150.3e170.0 nM), respectively, based on the plasma protein
binding ratios in rats of 98.2%e99.0% for canagliﬂozin and 83%e84%
for tofogliﬂozin (12, 13). Thus, plasma exposure to these com-
pounds was higher than the respective hSGLT2 IC50 values.4. Discussion
SGLT2 inhibitors reduce postprandial glucose levels in patients
with T2DM by increasing excretion of glucose in urine. Although
the plasma concentrations of most SGLT2 inhibitors are insufﬁ-
ciently high to inhibit SGLT1, some do show weak or moderate
SGLT1 inhibitory activity in vitro. We hypothesized that oral
administration of these SGLT2 inhibitors would inhibit small in-
testinal SGLT1 to increase luminal glucose concentrations, which
would in turn stimulate the release of GLP-1 from intestinal L-cells.
In the present study, we demonstrated that oral administration of
structurally different SGLT2 inhibitors, when combined with DPP4
inhibitors, effectively elevated plasma aGLP-1 levels in both normal
and diabetic rodents. Unlike with metformin, this aGLP-1 elevation
was also dependent on oral glucose-loading, suggesting a possible
involvement of intestinal SGLT1 inhibition in the enhanced GLP-1
secretion.
Fig. 3. Effects of GTB and metformin on plasma glucose, insulin, and aGLP-1 levels during OGTT in DPP4-deﬁcient F344 rats. (A) Time course (upper panel) and peak (lower panel) of
plasma glucose levels. (B) Time course (upper panel) and peak (lower panel) of plasma insulin levels. (C) Time course (upper panel) and DAUC0e5h (lower panel) of relative plasma
aGLP-1 levels. GTB (10, 30 mg/kg), metformin (300 mg/kg) and glucose solutions (2 g/kg) were simultaneously administered to 9-week-old F344/DuCrlCrlj rats at time 0 by oral
gavage. Data are presented as the mean ± SEM. (N ¼ 6). *P < 0.05, **P < 0.01 vs vehicle group by t-test; ##P < 0.01 vs vehicle group by one-way ANOVAwith Dunnett's post hoc test.
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when combined with sitagliptin, increase plasma aGLP-1 levels
after glucose-loading in SD rats (7). In this study, GTB and TA-1887
in combination with a DPP4 inhibitor similarly enhanced glucose-
induced aGLP-1 elevation in F344 rats. The glucoside structures of
these SGLT2 inhibitors are different: phloridzin is an O-glucoside,
canagliﬂozin and GTB are C-glucosides, and TA-1887 is an N-
glucoside. Canagliﬂozin has moderate hSGLT2/hSGLT1 selectivity
(IC50 ratio ¼ 158), favorable pharmacokinetic proﬁle, and glucose-
lowering effect. Compared with canagliﬂozin, GTB has higher
selectivity (IC50 ratio ¼ 644) and TA-1887 has more potent inhibi-
tory activity against hSGLT1 (TA-1887 ¼ 230 nM;
canagliﬂozin ¼ 663 nM). In addition, TA-1887 has similar phar-
macokinetic properties, such as Cmax, half-life, and bioavailability,
similar to those of canagliﬂozin, and increased urinary glucose
excretion (UGE) in normal rats and exhibited antihyperglycemic
effects in diabetic mice (14, 15). Although the pharmacokinetic
parameters of GTB have not been measured to date, it also pro-
moted UGE in normal rodents in a dose-dependent manner (un-
published data). This study demonstrated that structural variation
in the glucosides did not affect the elevating effect of GLP-1. In
addition, GTB did not affect plasma aGLP-1 levels in control con-
ditions, but did increase them under DPP4 inhibition and in DPP4-
deﬁcient animals. Equally, canagliﬂozin and TA-1887 also resulted
in postprandial plasma GLP-1 elevationwhen combinedwith any of
the DPP4 inhibitors, indicating that structurally different SGLT2
inhibitors enhance plasma GLP-1 levels by promoting GLP-1
secretion, provided there is sufﬁcient DPP4 inhibition. Thus, we
conclude that the increase of plasma aGLP-1 levels is the commonpharmacological effect of combination treatment with SGLT/DPP4
inhibitors.
In the present study, combination treatment with GTB and CMA
signiﬁcantly enhanced plasma aGLP-1 elevations in both normo-
glycemic rats and diabetic db/db mice relative to that with CMA
treatment alone. db/db mice develop hyperphagic obesity and
nonketotic diabetes and are used as amurinemodel of spontaneous
T2DM (9). This result is consistent with previous data obtained in
ZDF rats treated with canagliﬂozin and sitagliptin (7). These ﬁnd-
ings suggested that combined treatment with SGLT/DPP4 inhibitors
induces plasma aGLP-1 elevation in both normal and diabetic
rodents.
Metformin, an antidiabetic drug that reduces glycated hemo-
globin (HbA1c) by suppressing hepatic gluconeogenesis and
improving glucose uptake, has been shown to increase plasma
aGLP-1 levels in clinical and nonclinical studies (8). However, the
mechanism underlying metformin-induced GLP-1 elevation is
controversial. In the present study, we showed that metformin
increased plasma aGLP-1 levels independent of glucose-loading in
DPP4-deﬁcient rats, suggesting that metformin directly stimulated
GLP-1 secretion in L-cells via DPP4-independent mechanism. By
contrast, GTB did not affect basal GLP-1 levels, but it did enhance
glucose-induced GLP-1 elevation. This indicates that the metformin
and GTB caused GLP-1 to increase through different mechanisms.
Canagliﬂozin, at a dose of 3 mg/kg, and while under DPP4 inhibi-
tion, prolonged the elevation of plasma aGLP-1 during OGTT and
signiﬁcantly increased glucose content within the small intestine
after sucrose-loading. These data may support the idea that SGLT2
inhibitors, GTB, and canagliﬂozin, could increase plasma GLP-1
Fig. 4. Effects of GTB and metformin on plasma glucose, insulin, and aGLP-1 levels without glucose-loading in DPP4-deﬁcient F344 rats. (A) Time course of plasma glucose levels. (B)
Time course of plasma insulin levels. (C) Time course (upper panel) and DAUC0e5h (lower panel) of relative plasma aGLP-1 levels. GTB (10 and 30 mg/kg), metformin (300 mg/kg),
and water instead of glucose were administered simultaneously to 9-week-old F344/DuCrlCrlj rats at time 0 by oral gavage. Data are presented as the mean ± SEM. (N ¼ 6).
**P < 0.01 vs vehicle group by t-test; #P < 0.05 vs vehicle group by one-way ANOVA with Dunnett's post hoc test.
Fig. 5. Effects of canagliﬂozin and TA-1887 combined with a DPP4 inhibitor on plasma aGLP-1 levels during OGTT in normal F344 rats. (A) Relative plasma aGLP-1 levels 2 h after
glucose-loading when administered with canagliﬂozin and TA-1887 combined with teneligliptin. (B) Relative plasma aGLP-1 levels 2 h after glucose-loading when administered
with canagliﬂozin and TA-1887 combined with sitagliptin. Canagliﬂozin (30 mg/kg), TA-1887 (30 mg/kg), teneligliptin (5 mg/kg), sitagliptin (10 mg/kg), and glucose solution (2 g/
kg) were simultaneously administered to 9-week-old F344/NSlc rats at time 0 by oral gavage. Data are presented as the mean ± SEM. (N ¼ 5e6). *P < 0.05, **P < 0.01 vs teneligliptin
group; ##P < 0.01 vs sitagliptin group by one-way ANOVA followed by t-test.
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ﬂozin, and TA-1887 are potent SGLT2 inhibitors, they also share
mild or moderate inhibitory effects on hSGLT1. They are likely to
show similar inhibitory activity against rodent SGLT1 because other
SGLT2 inhibitors structurally close to GTB have shown no appre-
ciable inter-species differences between humans and rodents (16,
17). Moreover, after a glucose-containing meal challenge, an in-
crease in GLP-1 concentration was observed in SGLT1-deﬁcient
mice, but not in SGLT2-deﬁcient mice (18). These data suggested
that inhibition of SGLT2 does not contribute to plasma aGLP-1
elevation. These data support the idea that the GLP-1-elevating
effect of SGLT2 inhibitors is related to their SGLT1 inhibition.
As an index for glycemic control to prevent macro- and micro-
vascular complications, the roles of 2 h postprandial glucose,
HbA1c, and fasting glucose levels arewell documented. Elevation of
the postprandial glucose level is a risk factor for the onset or pro-
gression of macroangiopathy. The present study demonstrated that
combined treatment with structurally different SGLT2 inhibitors
and DPP4 inhibitors act to reduce postprandial glucose excursions
compared with the use of DPP4 inhibitors alone. SGLT2 and DPP4
inhibitors have different mechanisms of action for reducing plasma
glucose levels and, because these actions are glucose-dependent,
they are associated with a low risk of inducing hypoglycemia.
Furthermore, moderate SGLT1 inhibitionwould partly contribute to
the reduction of glucose excursions by delaying intestinal glucose
absorption. In patients with T2DM, blood glucose levels rise grad-
ually with time, making long-term maintenance of glycemic con-
trol difﬁcult with a single oral antidiabetic agent; however,
combination therapy with several agents can increase the risk of
hypoglycemia. Combination therapy with a DPP4 inhibitor and an
SGLT2 inhibitor might, therefore, be an effective and relatively safe
therapeutic alternative for better glycemic control in patients with
T2DM.
Chronic hyperglycemia impairs beta-cell function through glu-
cotoxic mechanisms and the induction of structural disorganization
in pancreatic islets. We showed that repeated administration of
canagliﬂozin increased insulin levels in beta-cells and minimized
the deterioration in islet structure in ZDF rats by ameliorating the
progression of hyperglycemia (16). GLP-1 exhibits similar antidia-
betic effects, including the protection of pancreatic function, so
elevated levels after co-administration of canagliﬂozin with a DPP4
inhibitor might potentiate these protective effects. To explore
whether plasma aGLP-1 elevation prevents pancreatic dysfunction
in diabetic animals, the effects of long-term treatment with SGLT2/
DPP4 inhibitors should be examined.
In summary, we showed that enhancement of glucose-induced
plasma aGLP-1 elevation is the common pharmacological effect of
structurally different SGLT2 inhibitors when co-administered with
DPP4 inhibitors, regardless of their chemical structure. Based on
this and the results of our previous studies, we propose the
following hypothetical mechanism. First, SGLT2 inhibitors with
moderate SGLT1 inhibitory activity transiently delay glucose ab-
sorption in the small intestine, and the non-absorbed glucose then
stimulates GLP-1 secretion from L-cells in the lower gastrointes-
tinal tract. Subsequently, DPP4 inhibitors likely prevent aGLP-1
degradation and prolong its half-life in the systemic circulation.
Finally, mediated by SGLT1 inhibition in the small intestine, aGLP-1
enhances glucose-induced insulin secretion, protects against
pancreatic beta-cell failure, and exerts multifunctional antidiabetic
effects. It appears that canagliﬂozin exerts these effects at a dose
that gives plasma drug concentrations equivalent to those in clin-
ical practice. Thus, combination therapy with a DPP4 inhibitor and
an SGLT2 inhibitor could provide better glycemic control for pa-
tients with T2DM.Conﬂicts of interest
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